LANTUS is a long- acting human insulin analog indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Diabetics who used Lantus had a 2.9-fold greater chance of cancer, while those who took the generic drug metformin had an 8 percent lower risk, according to the study presented yesterday at the San Antonio Breast Cancer Symposium. Researchers examined medical records of 23,266 patients in southern Sweden.
The drug's maker noted flaws in the study. The population was too small and had flaws that make it impossible to definitively address any potential risk from Lantus, according to Riccardo Perfetti, vice president for medical affairs at Sanofis.
The drug's label is found at various sites, including this one: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=39109
Read more at the source: http://www.bloomberg.com/news/2011-12-06/sanofi-s-lantus-doubled-risk-of-cancer-in-study-of-diabetics-study-finds.html?cmpid=yhoo
